Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the recent data presented at the 2023 AACR Conference on Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) in hepatocellular carcinoma.

Ticker(s): RHHBY

Who's the expert?

Institution: Private Practice

12 years of academic practice specializing in medical oncology.
treats 18 patients with unresectable hepatocellular carcinoma
familiar with both the HIMALAYA Phase III trial and the STRIDE regimen

Interview Goal

discussing the standard of care and the recent data presented at the 2023 AACR Conference on Roche/Genentech's Tecentriq (atezolizumab) plus Avastin (bevacizumab) for the prevention of certain types of returning adjuvant liver cancers and the Phase III IMbrave050 study data just presented at AACR2023 on Tecentriq (atezolizumab) plus Avastin (bevacizumab) in HCC.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.